[Lys40(Ahx-DTPA-111In)NH2]-exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma

Clinical Cancer Research

Volumn 13, Issue 12, 2007, Pages 3696-3705

  Wicki, Andreas ^a   Wild, Damian ^b   Storch, Daniel ^b   Seemayer, Christian ^c   Gotthardt, Martin ^d   Behe, Martin ^e   Kneifel, Stefan ^b   Mihatsch, Michael J ^c   Reubi, Jean Claude ^f   Mäcke, Helmut R ^b   Christofori, Gerhard ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EXENDIN 4 [40 LYSINE AMINOHEXANOIC ACID PANTENIC ACID IN 111]AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INDIUM 111; UNCLASSIFIED DRUG; (LYS(40)(AHX DTPA 111IN)NH2)EXENDIN 14; (LYS(40)(AHX-DTPA-111IN)NH2)EXENDIN-14; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; INDIUM; ORGANOMETALLIC COMPOUND; PENTETIC ACID; PEPTIDE; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUGER ELECTRON SPECTROSCOPY; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; INSULINOMA; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; THERAPY EFFECT; TRANSGENIC MOUSE; TUMOR VOLUME; ANIMAL; DRUG EFFECT; METABOLISM; PANCREAS TUMOR; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; CELL PROLIFERATION; FEMALE; INDIUM RADIOISOTOPES; INSULINOMA; MALE; MICE; MICE, TRANSGENIC; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; PENTETIC ACID; PEPTIDES; RADIOPHARMACEUTICALS; RECEPTORS, GLUCAGON; TISSUE DISTRIBUTION;

EID: 34250722229     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2965     Document Type: Article

References (32)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
2. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781-93.
3. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma-incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991;66:711-9.
4. Hirshberg B, Cochran C, Skarulis MC, et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer 2005;104:264-72.
5. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610-6.
6. 111Inoctreotide scintigraphy in oncology. Digestion 1993;54 Suppl 1:84-7.
7. Gotthardt M, Fischer M, Naeher I, et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging 2002;29:597-606.
8. 2]-Exendin-4, a very promising ligand for glucagon-like-peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006;47:2025-33.
9. Hanahan D. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315:115-22.
10. Kassis AI, Howell RW, Sasry KSR, Adelstein SJ. Positional effects of Auger decays in mammalian cells in culture. In: Baverstock KF, Charlton DE, editors. DNA damage by Auger emitters. London: Taylor & Francis; 1988. p.1-14.
11. Kereiakes JG, Rao DV. Auger electron dosimetry. Med Phys 1992;19:1359.
12. 125I compared with that of densely ionising α-particles. Lancet 1989;2:650-3.
13. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: absorbed fractions for monoenergetic electron and α particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 1994;35:303-16.
14. Jaaskela-Saari HA, Grenman R, Ramsay HA, Tarkkanen J, Paavonen T, Kairemo KJ. Indium-111-bleomycin complex in squamous cell cancer xenograft tumors of nude mice. Cancer Biother Radiopharm 2005;20:426-35.
15. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 2000;41:429-38.
16. Ochakovskaya R, Osorio L, Goldenberg DM, Mattes MJ. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium. Clin Cancer Res 2001;7:1505-10.
17. 111In-labeled antibodies to HER-2. Mol Cancer Ther 2005;4:927-37.
18. Behr TM, Behe M, Lohr M, et al. Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med 2000;27:753-65.
19. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110-22.
20. Loevinger R. MIRD primer for absorbed dose calculations. New York: Society of Nuclear Medicine; 1988.
21. Moré JJ. The Levenberg-Marquardt algorithm: implementation and theory. In: Watson G, editor. Lecture notes in mathematics. Berlin: Springer; 1978.
22. Moré JJ, Garbow BS, Hillstrom KE. Testing unconstrained optimization software. ACM Trans Math Software 1981;7:17-41.
23. Behr TM, Goldenberg DM. Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides? J Nucl Med 1996;37:834-6.
24. Kolby L, Bernhardt P, Johanson V, et al. Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour. Br J Cancer 2005;93:1144-51.
25. Herzig M, Savarese F, Novatchkova M, et al. Tumor progression induced by the loss of E-cadherin independent of β-catenin/Tcf-mediated Wnt signalling. Oncogene 2006. Epub ahead of print, DOI: 10.1038/sj.onc.1210029.
26. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-12.
27. Parangi S, O'Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A 1996;93:2002-7.
28. Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994;369:414-8.
29. Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 2000;60:7163-9.
30. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. JClin Oncol 2005;23:939-52.
31. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
32. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.